DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

 

Oncology Homepage

MR could predict survival and treatment response for patients with brain metastasis May spare them life-threatening surgeries

Brainlab to become distributor of Elekta's stereotactic neurosurgery products in US Already the supplier in select European markets

New nanoparticle technology may replace MR for cancer detection Shows promise in preclinical study

Study finds bi-annual MR exams better option for young women with genetic risk Annual mammogram may not be necessary

Study finds tomosynthesis is ultimately less expensive than digital mammography Diagnosis-related costs need to be considered

California Proton Therapy Center re-launches California Protons Consists of new management and leadership and an expanded group of physicians

Community practices not abiding by breast cancer screening guidelines for MR High breast density isn't enough

Volpara brings quality control and better risk assessment to breast imaging Launches two new products as part of VolparaEnterprise platform at RSNA

Study finds Transpara deep learning CAD system performs as well as radiologists ScreenPoint solution provides cancer suspicion score from 0 to 100

Elekta delays order target for Unity MR linac Making 'difficult' short-term decisions to benefit long term

TomoTherapy from Accuray

Accuray’s TomoTherapy more effective than Varian’s RapidArc, non-randomized study finds

by Lisa Chamoff , Contributing Reporter
A prospective study out of France has found that intensity-modulated radiation therapy (IMRT) using helical tomotherapy delivered with Accuray’s TomoTherapy System was more effective and produced fewer side effects in head and neck cancer patients than volumetric-modulated arc therapy, using Varian’s RapidArc radiotherapy technology.

The study, published in the International Journal of Radiation Oncology * Biology * Physics and funded by the French National Institute of Cancer, was conducted at 14 French centers between February 2010 and February 2012, and included 166 patients, 74 of which were treated using the TomoTherapy System and 92 who were treated using RapidArc.

Story Continues Below Advertisement

qualiTEE - reliabiliTEE - repairabiliTEE - we guaranTEE

Bayer HealthCare Multi Vendor Service will repair your transducer with the same precision and care you provide to your patients. Now offering TotalREPAIR on 140 transducer models! Call us at 1-844-5100 or visit www.mvs.bayer.com to set up an order today.



The locoregional control rate, or local control without any nodal recurrence, after 18 months was significantly better in the TomoTherapy patient group, at 83.3 percent, than in the RapidArc group, at 72.7 percent.

The cancer specific survival rate and post-treatment salivary gland function were also better in the TomoTherapy group.

The study’s lead author, Dr. Jean-Emmanuel Bibault, a radiation oncologist at Georges-Pompidou European Hospital in Paris, said that after performing a cost analysis of TomoTherapy and volumetric-modulated arc therapy — both forms of IMRT and considered the standard of care for head and neck cancer radiotherapy — and finding that TomoTherapy is more expensive, they decided to see if the difference in cost translated into any benefit for patients.

“We must admit that we did not expect these results, because TomoTherapy and RapidArc are considered very similar,” Bibault told HCB News. “But we actually showed in our prospective study that TomoTherapy did better for local control, with less side effects. We had already showed that TomoTherapy gave more homogeneous treatment than RapidArc, and this could be one of the explanations for this difference.”

Bibault stressed that the results should be further explored in a randomized trial. A randomized trial was not possible this time due to the availability of the equipment.

“We don't have any plans for a randomized study because they are very expensive and hard to perform in radiation oncology, because most of the time, a treatment center doesn't have a TomoTherapy and a RapidArc, but we certainly think this kind of study would be very interesting,” Bibault said. “Until a randomized trial compares these two techniques, I don't think it will change practice. However, this study is a worldwide first and raises the question of the importance of the way we perform IMRT.”
  Pages: 1 - 2 >>

Oncology Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2017 DOTmed.com, Inc.
ALL RIGHTS RESERVED